News for Kuros Biosciences AG (CSBTF)

Revenue Growth: 136% top line growth of MagnetOs sales.EBITDA: $9 million, with an 11.9% margin adjusted after the Fibrin-PTH write-off.Surgeon Utilization: In

Mar 11, 2025 / 02:00PM GMTChris Fair - Kuros Biosciences AG - Chief Executive Officer, Member of the Executive Board Welcome and thank you for attending our pre

Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeri

Increasing demand for minimally invasive surgeries, rapid advancements in surgical tools, & devices along with the growing incidence of chronic illness and...

Aug 15, 2024 / 01:00PM GMTChris Fair - Kuros Biosciences AG - Chief Operating Officer, Member of the Executive Board Okay, as people are coming into the meeting

Kuros Biosciences AG / Key word: AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren , Switzerland, April 17, 2024...

Kuros Biosciences AG / Key word: Annual Results Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 13-March-2024 /...

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Kuros Biosciences Reports Results for First Half 2023 Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2...

Kuros Biosciences The future of spinal fusions Investor Webcast - H1 2023 Earnings and Operational Update August 23,...

/PRNewswire/ --The orthobiologics market is expected to grow by USD 2,638.44 million from 2022 to 2027, according to Technavio. As per the latest report, the...